Filing Overview
Registrant: Coeptis Therapeutics Holdings, Inc. The request metadata identifies “Z Squared Inc.,” but the filing names Coeptis Therapeutics Holdings, Inc. as the registrant. This Form 8-K reports events beginning October 23, 2023; it is not a periodic financial report.
Material Financing Transaction
- On October 23, 2023, the company entered into a securities purchase agreement with an institutional investor for a private placement.
- The transaction included 777,000 common shares, pre-funded warrants for 1,223,000 shares, Series A warrants for 2,000,000 shares, and Series B warrants for 2,000,000 shares.
- The purchase price was $1.00 per share unit and $0.999 per pre-funded warrant unit.
- Series A and Series B warrants have an exercise price of $1.36 per share and become exercisable on the earlier of shareholder approval or April 26, 2024. Series A warrants expire after 18 months; Series B warrants expire after 5.5 years.
- Pre-funded warrants are immediately exercisable at $0.001 per share until fully exercised.
- Net proceeds were approximately $1.73 million after placement-agent fees and expenses, but before the company’s estimated offering expenses. Proceeds are intended for product development and general corporate purposes, including working capital.
Fees, Amendments, and Registration Obligations
- Ladenburg Thalmann & Co. Inc. acted as exclusive placement agent and received an 8.0% cash fee, a 1.0% management fee, $62,589 of legal fees, and warrants to purchase 120,000 shares at $1.40 per share. These warrants are exercisable upon the effective date and expire after five years.
- The company amended existing Series A and Series B warrants covering up to 3,062,500 shares each. Their exercise price was reduced from $1.65 to $1.36 per share, and the initial exercise date was changed to the earlier of shareholder approval or April 26, 2024.
- Under the registration rights agreement, the company agreed to file a registration statement within 20 calendar days of closing and use best efforts to obtain effectiveness within specified deadlines. Customary liquidated damages may apply for missed requirements.
- The securities and underlying shares were issued in an unregistered offering relying on Section 4(a)(2) and/or Rule 506 of the Securities Act.
Financial Metrics and Period Comparison
The filing does not provide revenue, net income, operating margins, cash flow, balance-sheet cash, debt, liquidity ratios, or other periodic financial results. Accordingly, no comparison with a prior period is available. The principal disclosed liquidity event is the approximately $1.73 million of net financing proceeds.
Outlook, Risks, and Unusual Items
- Management stated that proceeds will support continued product development and general corporate purposes, including working capital.
- The financing creates substantial potential dilution from the issued shares, pre-funded warrants, Series A warrants, Series B warrants, amended existing warrants, and placement-agent warrants.
- Registration deadlines and potential liquidated damages create execution obligations for the company.
- Exercise of the warrants is subject to the stated timing provisions, including potential shareholder approval. The filing does not provide a broader financial forecast or operating guidance.
Investor Verification Items
- Confirm the correct issuer identity, because the supplied metadata refers to Z Squared Inc. while the filing identifies Coeptis Therapeutics Holdings, Inc. and ticker symbols COEP and COEPW.
- Review the definitive purchase, warrant, registration-rights, placement-agency, and warrant-amendment agreements for complete terms.
- Verify the closing date and actual receipt and use of the approximately $1.73 million in net proceeds.
- Assess fully diluted share count and potential dilution from all warrants, including the amended existing warrants.
- Monitor shareholder approval requirements, warrant exercise dates, registration-statement deadlines, and any applicable liquidated damages.